



2P43
1633

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Transmittal (1 page) TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	09/412947-Conf. #1312
		Filing Date	October 5, 1999
		First Named Inventor	Sudhir AGRAWAL
		Art Unit	1633
		Examiner Name	J. L. Epps Ford
Total Number of Pages in This Submission	4	Attorney Docket Number	HYZ-050CP2 (47508.446US8)

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Interview Summary
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	Return Receipt Postcard
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	WILMER CUTLER PICKERING HALE AND DORR LLP		
Signature			
Printed name	Ann-Louise Kerner, Ph.D.		
Date	February 28, 2006	Reg. No.	33,523

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Dated: February 28, 2006	Signature: (Stephanie R. Douglas)



PATENTS
Atty. Docket No. HYZ-050CP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Sudhir Agrawal	Art Unit:	1633
Serial No.:	09/412,947	Examiner:	Epps Ford, J.
Filing Date:	October 5, 1999	Conf. No.	1312
Title:	Modified Protein Kinase A- Specific Oligonucleotides and Methods of Their Use	Customer No.:	23483

CERTIFICATE OF MAILING (37 C.F.R. § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: 28 Feb 2006

By: Stephanie R. Douglas

Stephanie R. Douglas

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INTERVIEW SUMMARY

Applicant thanks the Examiner for her time for participating in telephonic interviews on December 21 and 22, 2005. Responsive to the communication dated January 30, 2006, Applicant respectfully submits the following Interview Summary.

INTERVIEW SUMMARY

On December 21 and 22, 2005, telephonic interviews were held with me, Ann-Louise Kerner, Ph.D., participating on behalf of Applicant, and Examiner Janet Epps Ford, participating from the United States Patent and Trademark Office. Alison Corkery also participated on behalf of Applicant in the telephonic interview on December 21, 2005.

At the interview on December 22, 2005, I indicated that the proposed Examiner's amendment, which amended independent claim 55 to recite a "first therapeutic agent comprising a synthetic, modified antisense oligonucleotide fully complementary to at least 15 consecutive nucleotides of nucleic acid sequence GCCAGTGAGGAGGCACGC (SEQ ID NO:11) encoding N-terminal codons 8-13 of protein kinase A subunit RI α ," looked accurate based on our conversation. (Similar amendments to claims 56 and 57 were also made, claims 1-20, 23-48, and 52-54 were cancelled, and new claims 101 and 102 were added.)


CONCLUSIONS

Applicant notes that the claims are in condition for allowance. Furthermore, nothing in this paper should be construed as an intent to concede any issue with regard to any claim, unless specifically stated in this paper, and the amendment of any claim does not necessarily signify concession of unpatentability of the claim prior to its amendment.

No fees are believed to be due with this submission; however, please charge any underpayments or credit any overpayments for this Interview Summary to our Deposit Account No. 08-0219.

If the Examiner believes that any further discussion of this communication would be helpful, she is invited to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ann-Louise Kerner, Ph.D.
Reg. No. 33,523

Date: February 28, 2006
WILMER CUTLER PICKERING
HALE AND DORR LLP
60 State Street
Boston, MA 02109
Tel: (617) 526-6000
Fax: (617) 526-5000